NCT03523351
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Radiation Therapy
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Bone
Additional Notes: Patient must have high risk bone metastases that are asymptomatic or minimally symptomatic
Exclusions: Patients with leptomeningeal disease
https://ClinicalTrials.gov/show/NCT03523351